Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Champions Oncology, Inc.NASDAQ: CSBR
Revenue · Q3 FY2026 · quarter ended Jan 2026
Revenue declines year over year
Q3 FY2026 revenue of $16.56M fell 2.8% year over year, behind the -1.1% change in trailing-twelve-month revenue. Sequentially, it rose 10.1% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $58.53M (+2.8%) for the fiscal year ending Apr 2026, a slowdown from the +13.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJan 2026
- $16.56M+10.1% QoQ
- Last fiscal yearApr 2025
- $56.94M+13.5% YoY
- LTMJan 2026
- $57.94M-1.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.8% | +4.3% | +7.1 pp |
| 1 year | +13.5% | +2.8% | -10.8 pp |
| 3-year CAGR | +5.1% | +7.5% | +2.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 56.94M USD
- Year-over-year change
- +13.5%
- 4-year CAGR
- +8.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 56.94M | +13.5% |
| FY2024 | 2024-04-30 | 50.16M | -6.9% |
| FY2023 | 2023-04-30 | 53.87M | +9.7% |
| FY2022 | 2022-04-30 | 49.11M | +19.7% |
| FY2021 | 2021-04-30 | 41.04M | — |
Revenue vs competitors
How CSBR compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -1.1% is the 2nd highest of 7, against a peer median of -83.4%.
- Over three fiscal years its annual growth of +5.1% compares with a peer median of +14.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $99.61M USD | +49.9% | +14.8% | |
| LTM Jan 2026 | $57.94M USD | -1.1% | +5.1% | |
| LTM Mar 2026 | $23.14M USD | -88.4% | +23.9% | |
| LTM Mar 2026 | $1M USD | -78.3% | +15.3% | |
| FY2025 | $64K USD | -99.8% | — | |
| LTM Mar 2026 | €29.33K EUR | -77.4% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — |
| LTM Mar 2026 | $0 USD | -100.0% | -9.6% | |
IMAImageneBio Inc | LTM Mar 2026 | $0 USD | — | -62.9% |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $0 USD | — | — |
| Peer median (excluding CSBR) | — | -83.4% | +14.8% | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Revenue | 41.04M | 49.11M | 53.87M | 50.16M | 56.94M |
| Cost of Revenue | 21.45M | 23.63M | 29.53M | 29.4M | 28.39M |
| Gross Profit | 19.59M | 25.48M | 24.34M | 20.75M | 28.56M |
| Gross Margin | 47.7% | 51.9% | 45.2% | 41.4% | 50.1% |
| Research & Development | 7.2M | 9.37M | 11.55M | 9.54M | 6.83M |
| Selling, General & Admin | 12.03M | 15.5M | 17.24M | 18.13M | 16.88M |
| Operating Expenses | 19.23M | 24.87M | 28.79M | 27.68M | 23.71M |
| Depreciation & Amortization | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M |
| EBITDA | 1.55M | 2.21M | (3.02M) | (5.44M) | 6.27M |
| EBITDA Margin | 3.8% | 4.5% | -5.6% | -10.8% | 11.0% |
| Operating Income | 366K | 607K | (4.45M) | (6.92M) | 4.85M |
| Operating Margin | 0.9% | 1.2% | -8.3% | -13.8% | 8.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 71K | (24K) | (818K) | (387K) | (220K) |
| Income Before Tax | 437K | 583K | (5.27M) | (7.31M) | 4.63M |
| Pre-Tax Margin | 1.1% | 1.2% | -9.8% | -14.6% | 8.1% |
| Income Tax Expense | 75K | 35K | 68K | (32K) | (75K) |
| Net Income | 362K | 548K | (5.34M) | (7.28M) | 4.7M |
| Net Margin | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% |
| EPS (Basic) | 0.03 | 0.04 | (0.39) | (0.54) | 0.34 |
| EPS (Diluted) | 0.02 | 0.04 | (0.39) | (0.54) | 0.33 |
| Weighted Avg Shares | 13.14M | 13.2M | 13.54M | 13.55M | 13.66M |
| Weighted Avg Shares (Diluted) | 14.57M | 14.16M | 13.54M | 13.55M | 14.27M |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.